(19)
(11) EP 3 183 578 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.07.2020 Bulletin 2020/29

(45) Mention of the grant of the patent:
03.06.2020 Bulletin 2020/23

(21) Application number: 15757396.5

(22) Date of filing: 21.08.2015
(51) International Patent Classification (IPC): 
A61N 5/10(2006.01)
C12Q 1/68(2018.01)
G01N 33/574(2006.01)
(86) International application number:
PCT/US2015/046301
(87) International publication number:
WO 2016/029117 (25.02.2016 Gazette 2016/08)

(54)

METHODS FOR THE EARLY DETECTION OF COLORECTAL CANCER

VERFAHREN ZUR FRÜHERKENNUNG VON KOLOREKTALKARZINOM

MÉTHODES DE DÉTECTION PRÉCOCE DU CANCER COLORECTAL


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 22.08.2014 US 201462040874 P

(43) Date of publication of application:
28.06.2017 Bulletin 2017/26

(73) Proprietors:
  • Abbott Laboratories
    Abbott Park, IL 60064 (US)
  • Hvidovre Hospital
    2650 Hvidovre (DK)
  • University of Copenhagen
    1165 Copenhagen (DK)
  • Rigshospitalet
    2100 Copenhagen Ø (DK)

(72) Inventors:
  • DAVIS, Gerard J.
    Wauconda, Illinois 60084 (US)
  • GAWEL, Susan H.
    LaGrange Park, Illinois 60526 (US)
  • YANG, Xiaoqing
    Buffalo Grove, Illinois 60089 (US)
  • NIELSEN, Hans Jørgen
    DK-2800 Lyngby (DK)
  • CHRISTENSEN, Ib Jarle
    DK-3400 Hillerød (DK)

(74) Representative: Modiano, Micaela Nadia et al
Modiano & Partners Thierschstrasse 11
80538 München
80538 München (DE)


(56) References cited: : 
EP-A1- 2 071 337
WO-A1-2006/015616
WO-A1-2007/071367
WO-A1-2010/127782
WO-A2-2009/074276
US-A1- 2012 021 929
EP-A2- 1 439 393
WO-A1-2006/066915
WO-A1-2010/054789
WO-A1-2012/115885
US-A1- 2006 154 245
   
  • CLEMENS GIESSEN ET AL: "Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer", TUMOR BIOLOGY, vol. 35, no. 10, 17 July 2014 (2014-07-17) , pages 10237-10248, XP055225960, CH ISSN: 1010-4283, DOI: 10.1007/s13277-014-2338-6
  • HELEN SWEDE ET AL: "Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort", INTERNATIONAL JOURNAL OF CANCER, vol. 134, no. 8, 15 April 2014 (2014-04-15), pages 1862-1870, XP055226470, US ISSN: 0020-7136, DOI: 10.1002/ijc.28504
  • KONSTANTINOS K. TSILIDIS ET AL: "C-reactive protein and colorectal cancer risk: A systematic review of prospective studies", INTERNATIONAL JOURNAL OF CANCER, vol. 123, no. 5, 1 September 2008 (2008-09-01), pages 1133-1140, XP055226465, US ISSN: 0020-7136, DOI: 10.1002/ijc.23606
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).